Goldman Sachs analyst Richard Law reiterated a Buy rating and $29.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE